Press Releases

Date Title    
Toggle Summary Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting
Toggle Summary Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock
Toggle Summary Editas Medicine, Inc., Announces Proposed Offering of Common Stock
Toggle Summary Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases
Toggle Summary Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update
Toggle Summary Editas Medicine Announces Departure of Chief Operating Officer
Toggle Summary Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2016 Corporate Update and Results
Toggle Summary Editas Medicine Joins Global Movement to Raise Awareness on Rare Disease Day 2017
Toggle Summary Editas Medicine to Present at Investor Conferences in March
Toggle Summary Editas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference
Toggle Summary Editas Medicine to Present at Upcoming February Investor Conferences
Toggle Summary Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference
Toggle Summary Editas Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference
Toggle Summary Editas Medicine Extends CRISPR Genome Editing Leadership Through Licensing of New CRISPR Technologies
Toggle Summary Editas Medicine to Present at the Stifel Healthcare Conference 2016
Toggle Summary Editas Medicine Announces Third Quarter 2016 Results and Update
Toggle Summary Editas Medicine to Host Conference Call Discussing Third Quarter 2016 Corporate Update and Results
Toggle Summary Editas Medicine to Present Data on CRISPR/Cas9-mediated Gene Editing in Hematopoietic Stem/Progenitor Cells at ESGCT-ISSCR 2016
Toggle Summary Editas Medicine Reports Inducement Grant to New Chief Medical Officer
Toggle Summary Editas Medicine to Present at the Jefferies Gene Editing/Therapy Summit
Toggle Summary Editas Medicine Expands Senior Management Team
Toggle Summary Editas Medicine to Present at the Morgan Stanley Global Healthcare Conference
Toggle Summary Editas Medicine Names Charles Albright as Chief Scientific Officer
Toggle Summary Editas Medicine Announces Second Quarter 2016 Results and Update
Toggle Summary Adverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing Medicines to the Eye
Toggle Summary Editas Medicine Announces Exclusive License to Advanced CRISPR Genome Editing Technology from Massachusetts General Hospital
Toggle Summary Editas Medicine to Host Conference Call Discussing Second Quarter 2016 Corporate Update and Results
Toggle Summary Editas Medicine Appoints Akshay Vaishnaw, M.D., Ph.D., to its Board of Directors
Toggle Summary Editas Medicine Announces Scientific Multi-Year Collaboration with Fondazione Telethon and Ospedale San Raffaele  
Toggle Summary Editas Medicine to Present at Upcoming June Investor Conferences
Toggle Summary Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines
Toggle Summary Editas Medicine Announces First Quarter 2016 Results and Update
Toggle Summary Editas Medicine to Host Conference Call Discussing First Quarter 2016 Corporate Update and Results
Toggle Summary Editas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics
Toggle Summary Editas Medicine Announces Presentations at Upcoming Scientific Conferences
Toggle Summary Editas Medicine to Present at Deutsche Bank 41st Annual Health Care Conference
Toggle Summary Editas Medicine to Present at 15th Annual Needham Healthcare Conference
Toggle Summary Editas Medicine Reports Fourth Quarter and Full Year 2015 Financial Results
Toggle Summary Editas Medicine to Present at Cowen and Company 36th Annual Health Care Conference
Toggle Summary Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares
Toggle Summary Editas Medicine Announces Pricing of Initial Public Offering
Toggle Summary Editas Medicine Appoints John D. Mendlein, Ph.D., to Board of Directors
Toggle Summary Editas Medicine Expands Leadership Team with Key Organizational Appointments
Toggle Summary Editas Medicine Comments in Connection with International Summit on Human Gene Editing
Toggle Summary Editas Medicine Raises $120 Million to Advance Genome Editing
Toggle Summary Editas Medicine Named A 2015 Technology Pioneer by World Economic Forum
Toggle Summary Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer
Toggle Summary Juno Therapeutics and Editas Medicine Announce Exclusive Collaboration to Create Next-Generation CAR T and TCR Cell Therapies
Toggle Summary Editas Medicine Presents Data from Multiple Therapeutic Discovery Programs Emerging from its Genome Editing Platform at the ASGCT Annual Conference
Toggle Summary Editas Medicine Announces Six Scientific Presentations at the American Society of Gene And Cell Therapy 18th Annual Meeting
Toggle Summary Vic Myer, Ph.D. Joins Editas Medicine as Chief Technology Officer
Toggle Summary Editas Medicine Reports Data Demonstrating the Potential of CRISPR/Cas9 to Enable Gene Repair Through a New Mechanism
Toggle Summary Editas Medicine Reports New Data Characterizing Novel Properties of Staphylococcus aureus Cas9 as a Tool for CRISPR-Based Genome Engineering
Toggle Summary Editas Medicine Licenses Genome Editing Technology from Broad Institute and Harvard University
Toggle Summary Editas Medicine Licenses Genome Editing Technology from Duke University